Patents Assigned to The University of Montana
  • Publication number: 20140197098
    Abstract: A process of growing a culture of cyanobacteria or algae using chitin or chitosan as a source of nitrogen for photosynthetic growth is described. This process can be used to remove pollutants from nitrogen-deficient natural waters or wastewaters. Biomass that results from photosynthetic growth on chitin can be used, either as whole cells or the isolated components of the cells, for a large variety of commercial purposes.
    Type: Application
    Filed: February 14, 2014
    Publication date: July 17, 2014
    Applicant: The University of Montana
    Inventors: Carrine Blank, Nancy W. Hinman
  • Patent number: 8673619
    Abstract: A process of growing a culture of cyanobacteria or algae using chitin or chitosan as a source of nitrogen for photosynthetic growth is described. This process can be used to remove pollutants from nitrogen-deficient natural waters or wastewaters. Biomass that results from photosynthetic growth on chitin can be used, either as whole cells or the isolated components of the cells, for a large variety of commercial purposes.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: March 18, 2014
    Assignee: The University of Montana
    Inventors: Carrine E. Blank, Nancy W. Hinman
  • Publication number: 20140066529
    Abstract: Silica polyamine composites (SPC) made from silanized amorphous nano-porous silica gel and poly(allylamine) (BP-1) were functionalized with phosphorus acid using the Mannich reaction, resulting in a phosphonic acid modified composite (BPAP). Zirconium (IV) was immobilized on BPAP. Arsenate anions strongly adsorbed on the ZrBPAP composite in the pH range 2 to 8, while arsenite only adsorbed well at pH 10. Regeneration of the resin was carried out successfully for As(V) and As(III) using 2M-H2SO4. Four adsorption/desorption cycles were performed for As(V) at pH 4 without significant decrease in the uptake performance. ZrBPAP capture capacity and kinetics for arsenate were tested for longevity over 1000 cycles with only a marginal loss of performance.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: The University of Montana
    Inventors: Edward Rosenberg, Varadharajan Kailasam, Daniel Nielsen
  • Patent number: 8623943
    Abstract: Hydroxypolyamides, hydroxypolyamide products, and post-hydroxypolyamides are disclosed as gel forming agents. Hydroxypolyamides and post-hydroxypolyamides are prepared from known methods. Hydroxypolyamide products are produced from a modified polymerization procedure which utilizes strong base for deprotonation of ammonium salts from the esterification of stoichiometrically equivalent polyacid:polyamine salts. The hydroxypolyamide products are capable of gel formation at lower concentrations than hydroxypolyamides and post-hydroxypolyamides from the known methods of preparation, and are therefore superior gel forming agents.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: January 7, 2014
    Assignee: The University of Montana
    Inventors: Donald E. Kiely, Tyler N. Smith
  • Publication number: 20130343994
    Abstract: The invention provides compounds that inhibit cholinesterases, such as acetylcholinesterase and butyrylcholinesterase. Such compounds are useful to prevent or treat exposure of a patient (e.g., a human) to an organophosphoric nerve agent (e.g., sarin and VX) or to treat a patient suffering from a neurodegenerative disorder such as Alzheimer's Disease or Lewy Body Dementia. The compounds are further useful as diagnostic tools for use in medical or research radiography (e.g., positron emission tomography) when synthesized with a radionuclide (e.g., [18F]. Synthetic schemes to produce such compounds are also provided.
    Type: Application
    Filed: June 25, 2013
    Publication date: December 26, 2013
    Applicant: THE UNIVERSITY OF MONTANA
    Inventors: Charles M. Thompson, John M. Gerdes, Syed K. Ahmed, Yamina Belabassi
  • Publication number: 20130261133
    Abstract: The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and trypanosoma infections, bacterial infections such as S. aureus and C. albicans, and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 3, 2013
    Applicant: The University of Montana
    Inventors: John Howard Hoody, David Brian Bolstad
  • Patent number: 8535528
    Abstract: Oxine ligands placed on styrene base ion exchange resins selectively remove iron and gallium from acidic solutions. After loading, the oxine resin is stripped of the loaded metals and used again for further metal removal. The resins can be used for process streams, acid rock drainages, or any other iron or gallium containing solution.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: September 17, 2013
    Assignee: Montana Tech of The University Of Montana
    Inventors: Paul J. Miranda, Corby G. Anderson, Edward Rosenberg
  • Patent number: 8343446
    Abstract: The oxine ligands 5-chloro-8-hydroxyquiniline and 5-sulfoxyl-8-hydroxyquinoline are covalently bound, using, for example, the Mannich reaction, to a silica gel polyamine composite made from a silanized amorphous silica xerogel and polyallylamine. The resulting modified composites, termed CB-1 (X?Cl) and SB-1 (X?SO3H), respectively, show a clear selectivity for trivalent over divalent ions and selectivity for gallium over aluminum. The compounds of the invention can be applied for the sequestration of metals, such as heavy metals, from contaminated mine tailing leachates.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: January 1, 2013
    Assignee: The University of Montana
    Inventors: Edward Rosenberg, Paul Miranda, Yuen Onn Wong
  • Patent number: 8150643
    Abstract: Real-time battery impedance spectrum is acquired using a one-time record. Fast Summation Transformation (FST) is a parallel method of acquiring a real-time battery impedance spectrum using a one-time record that enables battery diagnostics. An excitation current to a battery is a sum of equal amplitude sine waves of frequencies that are octave harmonics spread over a range of interest. A sample frequency is also octave and harmonically related to all frequencies in the sum. The time profile of this signal has a duration that is a few periods of the lowest frequency. The voltage response of the battery, average deleted, is the impedance of the battery in the time domain. Since the excitation frequencies are known and octave and harmonically related, a simple algorithm, FST, processes the time record by rectifying relative to the sine and cosine of each frequency. Another algorithm yields real and imaginary components for each frequency.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: April 3, 2012
    Assignees: Battelle Energy Alliance, LLC, Montana Tech of the University of Montana, Qualtech Systems, Inc.
    Inventors: John L. Morrison, William H. Morrison, Jon P. Christophersen
  • Patent number: 7998962
    Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radiolabelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: August 16, 2011
    Assignee: The University of Montana
    Inventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche
  • Publication number: 20110105621
    Abstract: A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions.
    Type: Application
    Filed: November 24, 2010
    Publication date: May 5, 2011
    Applicant: THE UNIVERSITY OF MONTANA
    Inventors: David J. Poulsen, Thomas Frederick Rau
  • Patent number: 7887784
    Abstract: Racemic mixtures and enantiomerically pure forms of novel 1-[(2?-substituted)-piperazin-1?-yl]-isoquinolines are norepinephrine (NE) transporter (NET) inhibitor compounds. Compounds of the invention are considered therapeutic agents for central nervous system (CNS) diseases and disorders, without limitation, including neurodegeneration, anxiety, depression, attention deficit disorders, drug dependency, and post traumatic stress disorder. Examples of the chemical syntheses of the compounds of the invention are provided. The isoquinoline compounds of the invention competitively bind at NET at nanomolar concentrations. The isoquinoline agents of the invention bind selectively to NET over other competitive transporter targets and receptor binding sites, including those of serotonin and dopamine, amongst others. The chemical syntheses of the invention are suitable for labeling with radionuclide atoms.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: February 15, 2011
    Assignee: University of Montana
    Inventors: John M. Gerdes, David B. Bolstad, Michael R. Braden, August W. Barany
  • Publication number: 20100272744
    Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.
    Type: Application
    Filed: April 9, 2010
    Publication date: October 28, 2010
    Applicant: THE UNIVERSITY OF MONTANA
    Inventors: RALPH C. JUDD, D. SCOTT MANNING
  • Patent number: 7812162
    Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radio-labelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: October 12, 2010
    Assignee: The University of Montana
    Inventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche
  • Patent number: 7794733
    Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: September 14, 2010
    Assignee: The University of Montana
    Inventors: Ralph C. Judd, D. Scott Manning
  • Patent number: 7692041
    Abstract: A controlled nitric acid process employing oxygen and nitric acid as co-oxidants is used to oxidize organic compounds subject to nitric acid oxidation, to their corresponding carboxylic acids. Oxidation of some carbohydrates by this process can produce one or more of their corresponding acid forms. The process is carried out at moderate temperatures, typically in the range of 20° C. to 45° C. in a closed reactor, with oxygen gas being introduced into the reaction chamber as needed in order to sustain the reaction. Computer controlled reactors allow for careful and reproducible control of reaction parameters. Nitric acid can be recovered by a distillation/evaporation process, or by diffusion dialysis, the aqueous solution made basic with inorganic hydroxide, and the residual inorganic nitrate removed using a filtration (nanofiltration) device.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: April 6, 2010
    Assignee: The University of Montana
    Inventors: Donald E. Kiely, Kirk R. Hash, Sr.
  • Patent number: 7662588
    Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: February 16, 2010
    Assignee: The University of Montana
    Inventors: Ralph C. Judd, D. Scott Manning
  • Patent number: 7395163
    Abstract: Real time battery impedance spectrum is acquired using one time record, Compensated Synchronous Detection (CSD). This parallel method enables battery diagnostics. The excitation current to a test battery is a sum of equal amplitude sin waves of a few frequencies spread over range of interest. The time profile of this signal has duration that is a few periods of the lowest frequency. The voltage response of the battery, average deleted, is the impedance of the battery in the time domain. Since the excitation frequencies are known, synchronous detection processes the time record and each component, both magnitude and phase, is obtained. For compensation, the components, except the one of interest, are reassembled in the time domain. The resulting signal is subtracted from the original signal and the component of interest is synchronously detected. This process is repeated for each component.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: July 1, 2008
    Assignee: Montana Tech of the University of Montana
    Inventors: John L. Morrison, William H. Morrison
  • Patent number: 7314906
    Abstract: A method of producing high molecular weight stereoregular head, tail-poly(alkylene D-glucaramides) is described. Amidoamino acids are esterified in cold alcohol and then polymerized in a protic solvent to form steroregular prepolymers. The prepolymers are then further polymerized by dissolving them in a solvent to form larger, purer postpolymers. Compositions of matter prepared using the subject method are also described.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: January 1, 2008
    Assignee: The University of Montana
    Inventors: Donald E. Kiely, Kylie Kramer
  • Patent number: 7314507
    Abstract: A metallic filter effectively removes mercury vapor from gas streams. The filter captures the mercury which then can be released and collected as product. The metallic filter is a copper mesh sponge plated with a six micrometer thickness of gold. The filter removes up to 90% of mercury vapor from a mercury contaminated gas stream.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: January 1, 2008
    Assignee: Montana Tech of The University of Montana
    Inventor: Kumar Ganesan